» Articles » PMID: 38566310

Global and Single-nucleotide Resolution Detection of 7-methylguanosine in RNA

Abstract

RNA modifications, including -7-methylguanosine (mG), are pivotal in governing RNA stability and gene expression regulation. The accurate detection of internal mG modifications is of paramount significance, given recent associations between altered mG deposition and elevated expression of the methyltransferase METTL1 in various human cancers. The development of robust mG detection techniques has posed a significant challenge in the field of epitranscriptomics. In this study, we introduce two methodologies for the global and accurate identification of mG modifications in human RNA. We introduce borohydride reduction sequencing (Bo-Seq), which provides base resolution mapping of mG modifications. Bo-Seq achieves exceptional performance through the optimization of RNA depurination and scission, involving the strategic use of high concentrations of NaBH, neutral pH and the addition of 7-methylguanosine monophosphate (mGMP) during the reducing reaction. Notably, compared to NaBH-based methods, Bo-Seq enhances the mG detection performance, and simplifies the detection process, eliminating the necessity for intricate chemical steps and reducing the protocol duration. In addition, we present an antibody-based approach, which enables the assessment of mG relative levels across RNA molecules and biological samples, however it should be used with caution due to limitations associated with variations in antibody quality between batches. In summary, our novel approaches address the pressing need for reliable and accessible methods to detect RNA mG methylation in human cells. These advancements hold the potential to catalyse future investigations in the critical field of epitranscriptomics, shedding light on the complex regulatory roles of mG in gene expression and its implications in cancer biology.

Citing Articles

Functions of METTL1/WDR4 and QKI as m7G modification - related enzymes in digestive diseases.

Zhou W, Yi Y, Cao W, Zhong X, Chen L Front Pharmacol. 2025; 15():1491763.

PMID: 39850560 PMC: 11754259. DOI: 10.3389/fphar.2024.1491763.

References
1.
Boccaletto P, Stefaniak F, Ray A, Cappannini A, Mukherjee S, Purta E . MODOMICS: a database of RNA modification pathways. 2021 update. Nucleic Acids Res. 2021; 50(D1):D231-D235. PMC: 8728126. DOI: 10.1093/nar/gkab1083. View

2.
Peattie D . Direct chemical method for sequencing RNA. Proc Natl Acad Sci U S A. 1979; 76(4):1760-4. PMC: 383470. DOI: 10.1073/pnas.76.4.1760. View

3.
Li L, Yang Y, Wang Z, Xu C, Huang J, Li G . Prognostic role of METTL1 in glioma. Cancer Cell Int. 2021; 21(1):633. PMC: 8627054. DOI: 10.1186/s12935-021-02346-4. View

4.
Lakings D, Waalkes T, BOREK E, GEHRKE C, Mrochek J, Longmore J . Composition, associated tissue methyltransferase activity, and catabolic end products of transfer RNA from carcinogen-induced hepatoma and normal monkey livers. Cancer Res. 1977; 37(1):285-92. View

5.
Torres A, Batlle E, Ribas de Pouplana L . Role of tRNA modifications in human diseases. Trends Mol Med. 2014; 20(6):306-14. DOI: 10.1016/j.molmed.2014.01.008. View